Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07548801

Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease

Background & Rationale:

Treatment options for Parkinson's Disease (PD) often face challenges due to the variety of clinical subtypes, differing individual responses, and disease progression. Given its portability, affordability, safety, and ease of use, cerebellar transcranial direct current stimulation (ctDCS) presents as a promising option for home-based treatment with medical telemonitoring in the near future.

Study Procedures:

Participants are invited to complete questionnaires regarding quality of life, anxiety and depression, and symptoms related to their PD.

On the first day, they will be assessed using the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III for motor impairment and the Cerebellar Cognitive Affective Syndrome scale (CCAS) for cognitive impairment. Participants will then undergo an additional 8 days of at-home cTDCS stimulation. On the 10th day, they will be reassessed using the MDS-UPDRS III and CCAS. One month later, they will complete again the questionnaires regarding quality of life, anxiety, depression, and symptoms related to their PD.

Objective:

Consequently, the primary goal is to investigate the effectiveness of ctDCS in addressing both motor and non-motor symptoms of PD

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

PARKINSON DISEASE (Disorder) Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinsonian Disorders Synucleinopathies

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hopital Erasme

Brussels, 1070, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with mild to moderate PD MDS-UPDRS part 1III or between 1 and 3 on Hoehn and Yahr score
  • Patients > 18 years of agE
  • Patients who have signed written informed consent

Exclusion criteria

  • Pregnant women
  • Patients ≤ 18 years of age
  • Presence of intracranial metallic hardware (e.g., vascular clips, orthopedic material)
  • Presence of an implanted electronic device (e.g., pacemaker, cochlear implants, deep brain stimulator)
  • History of epileptic seizures
  • Active or past neurological condition affecting upper limb control (e.g., stroke, degenerative disease, tumor, traumatic sequelae), or any neuromuscular (e.g., upper limb polyneuropathy, myopathy) or orthopedic condition impairing upper limb motor control
  • Subject unable to understand or perform the required motor tasks
  • Psychotropic polypharmacy (regular use of neuroleptics, anti-epileptics, benzodiazepines, etc.)

Treatment and study plan

cTDCS

Device

anodal cTDCS

Primary outcomes

  1. MDS-UPDRS (Unit on a scale)

    Time frame: day 1 to day 10 (MDS-UPDRS III) day 1 to day 40 (MDS-UPDRS Part I, II and IV)

    MDS-UPDRS Part III MDS-UPDRS Part I, II and IV

  2. CCAS (Unit on a scale)

    Time frame: day 1 and day 10

    CCAS scale

Secondary outcomes

  1. Feasibility and tolerability of ctDCS (Unit on a scale)

    Time frame: from day 1 to day 10

    participant-reported outcomes regarding the ease of self-administration and the presence of side effects are collected through a dedicated questionnaire.

  2. Scale evaluation anxiety (Unit on a scale)

    Time frame: day 1 and day 40

    anxiety as evaluated by Generalized Anxiety Disorder-7 (GAD-7)

  3. Scale evaluating depression (Unit on a scale)

    Time frame: day 1 and day 40

    depression as evaluated by Patient Health Questionnaire-9 (PHQ-9 )

  4. Quality of life (Unit on a scale)

    Time frame: day 1 and day 40

    quality of life as evaluated by Parkinson's Disease Questionnaire-39 (PDQ-39)

  5. Scale evaluation anxiety (Unit on a scale)

    Time frame: day 1 and day 40

    anxiety as evaluated by Beck Anxiety Inventory (BAI)

  6. Scale evaluating depression (Unit on a scale)

    Time frame: day 1 and day 40

    depression as evaluated by Beck Depression Inventory (BDI)

  7. Quality of life (Unit on a scale)

    Time frame: day 1 and day 40

    quality of life as evaluated by European Quality of Life 5 Dimensions (EQ-5D)

Sponsors and collaborators

Lead sponsor

Université Libre de Bruxelles

Other

Collaborators

  • Fonds National de la Recherche Scientifique

Registry information

Official study title

Can Cerebellar Transcranial Direct Current Stimulation be Regarded as a Rational Therapeutic Option for Treating Parkinson's Disease ?

Acronym: cTDCSinPD

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Apr 23, 2026
Registry last updated
Apr 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.